![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/01/2922903/0/en/Virios-Therapeutics-to-Report-Second-Quarter-2024-Financial-Results-on-Thursday-August-8-2024.html
https://www.globenewswire.com/news-release/2024/07/23/2917299/0/en/Virios-Therapeutics-Announces-Completion-of-Enrollment-in-IMC-2-Phase-2-Long-COVID-Study-Being-Conducted-by-Bateman-Horne-Center.html
https://www.globenewswire.com/news-release/2024/05/22/2886785/0/en/Virios-Therapeutics-Announces-Closing-of-1-7-Million-Public-Offering-of-Common-Stock-to-Commence-Preparations-for-Planned-IMC-2-Long-COVID-Phase-2b-Study.html
https://www.globenewswire.com/news-release/2024/05/20/2884603/0/en/Virios-Therapeutics-Announces-Pricing-of-1-7-Million-Public-Offering-of-Common-Stock-to-Commence-Preparations-for-Planned-IMC-2-Long-COVID-Phase-2b-Study.html
https://www.globenewswire.com/news-release/2024/05/17/2884480/0/en/Virios-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-to-Commence-Preparations-for-Planned-IMC-2-Long-COVID-Phase-2b-Study.html
https://www.globenewswire.com/news-release/2024/05/09/2878674/0/en/Virios-Therapeutics-Announces-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/02/2874307/0/en/Virios-Therapeutics-to-Report-First-Quarter-2024-Financial-Results-on-Thursday-May-9-2024.html
https://www.globenewswire.com/news-release/2024/03/26/2852441/0/en/Virios-Therapeutics-Announces-Publication-of-International-Patent-for-IMC-2-Covering-Antiviral-Treatment-of-Long-COVID.html
https://www.globenewswire.com//news-release/2024/02/29/2838080/0/en/Virios-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/28/2837048/0/en/Virios-Therapeutics-Issues-Shareholder-Letter-Highlighting-Corporate-Progress-and-Key-Upcoming-Milestones.html